Alvotech (ALVO)
NASDAQ: ALVO · Real-Time Price · USD
13.36
+0.09 (0.68%)
Jan 21, 2025, 4:00 PM EST - Market closed
Alvotech Revenue
Alvotech had revenue of $102.99M in the quarter ending September 30, 2024, with 478.60% growth. This brings the company's revenue in the last twelve months to $393.92M, up 517.92% year-over-year. In the year 2023, Alvotech had annual revenue of $93.38M with 9.84% growth.
Revenue (ttm)
$393.92M
Revenue Growth
+517.92%
P/S Ratio
8.58
Revenue / Employee
$394,313
Employees
999
Market Cap
4.03B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 93.38M | 8.37M | 9.84% |
| Dec 31, 2022 | 85.02M | 45.33M | 114.23% |
| Dec 31, 2021 | 39.68M | -29.77M | -42.86% |
| Dec 31, 2020 | 69.45M | -13.23M | -16.00% |
| Dec 31, 2019 | 82.68M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 87.70B |
| Merck & Co. | 63.17B |
| AbbVie | 55.53B |
| AstraZeneca | 51.21B |
| Novartis AG | 49.94B |
| Thermo Fisher Scientific | 42.37B |
| Abbott Laboratories | 41.22B |
ALVO News
- 4 weeks ago - Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024 - GlobeNewsWire
- 2 months ago - Alvotech's Position In The Coming Biosimilar Gold Rush - Seeking Alpha
- 2 months ago - Certain Closed-end Funds Advised by Franklin Templeton Fund Adviser, LLC Announce Appointment of New Chair and Directors - Business Wire
- 2 months ago - Alvotech (ALVO) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore's HealthCONx Conference on December 5, 2024 - GlobeNewsWire
- 2 months ago - European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab) - GlobeNewsWire
- 3 months ago - Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024 - GlobeNewsWire
- 3 months ago - European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva® - GlobeNewsWire